Autolus Therapeutics (NASDAQ:AUTL) Sees Large Volume Increase – Here’s Why

Autolus Therapeutics plc (NASDAQ:AUTL) shares saw an uptick in trading volume on Thursday . 5,096,923 shares changed hands during trading, an increase of 278% from the previous session’s volume of 1,349,308 shares.The stock last traded at $3.58 and had previously closed at $4.00.

Autolus Therapeutics Stock Performance

The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09. The stock has a 50 day simple moving average of $4.02 and a 200 day simple moving average of $4.05. The company has a market cap of $931.33 million, a price-to-earnings ratio of -3.02 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, analysts predict that Autolus Therapeutics plc will post -0.84 EPS for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Avoro Capital Advisors LLC bought a new position in Autolus Therapeutics in the 1st quarter worth approximately $78,765,000. Armistice Capital LLC lifted its position in Autolus Therapeutics by 33.8% in the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock worth $21,750,000 after purchasing an additional 1,578,000 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Autolus Therapeutics by 82.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after purchasing an additional 2,487,778 shares during the period. Affinity Asset Advisors LLC lifted its position in Autolus Therapeutics by 27.4% in the second quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock worth $14,964,000 after purchasing an additional 925,000 shares during the period. Finally, Great Point Partners LLC lifted its position in Autolus Therapeutics by 195.0% in the second quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock worth $11,977,000 after purchasing an additional 2,275,000 shares during the period. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.